https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3985770/ July 2012
The publisher's final edited version of this article is available at Int J Stroke
See other articles in PMC that cite the published article.
Abstract
Many
advances have been achieved in terms of understanding the molecular and
cellular mechanisms of ischemic stroke. But thus far, clinically
effective neuroprotectants remain elusive. In this minireview, we
summarize the basics of ischemic cascades after stroke, covering
neuronal death mechanisms, white matter pathophysiology, and
inflammation with an emphasis on microglia. Translating promising
mechanistic knowledge into clinically meaningful stroke drugs is very
challenging. An integrative approach that encompasses the multimodal and
multicell signaling phenomenon of stroke will be required to move
forward.
Keywords: microglia, neurovascular unit, penumbra, reperfusion, white matter
Introduction
Stroke and cerebrovascular disease is a major cause of mortality and disability worldwide (1,2).
Ischemic stroke is caused by a reduction in blood flow to the brain.
Hence, the decrease in cerebral blood flow (CBF) has received an
effective answer: accelerated reperfusion via thrombolysis using
recombinant tissue plasminogen activator (rt-PA) is associated with an
improved clinical outcome. This achievement is now routinely transferred
to practice.(NO it is not, maybe 5-10% get it) This ease of translation is due to the fact that the
underlying conceptual model is simple: an arterial occlusion decreases
CBF. So an effective treatment should increase CBF.
The
best way to do this currently might be with rt-PA. However, due to the
moderate recanalization rate, the limited time window, and the number of
contraindications for thrombolysis, only minority of patients receive
tPA so other treatments with potential additive effects are still
urgently needed. Furthermore, even in patients who receive tPA, those
with more severe initial strokes often do not significantly improve. In
part, this might be related to some aspect of reperfusion injury.
Overall, additive treatments that combine with rt-PA should be worth
pursuing.
In terms of the blood flow
distribution, cerebral ischemic strokes are often focal. In the central
core regions of the insult, there is almost total CBF arrest. This area
evolves rapidly toward death within minutes. Surrounding this core, CBF
levels may fall below functional thresholds yet transiently lie above
the threshold of cell death – this zone has been called the penumbra.
The penumbra, a metastable zone, permits only cell survival for a
certain period of time. Thus, this potentially salvageable tissue is the
target for neuroprotective therapy. Over the past two decades,
tremendous progress has been achieved in terms of understanding the
intricate cellular and molecular mechanisms of stroke pathophysiology (3,4).
However, to date, we still do not have a clinically effective
neuroprotectant. In this minireview, we briefly survey the fundamentals
of the ischemic cascade. Many excellent and more detailed reviews on
this topic have been published (5–7). Our more limited scope here is focused on an attempt to discuss translational hurdles and identify promising targets.
Much more at link with 115 references. I bet your doctor has not read a single one of those references.
No comments:
Post a Comment